New clinical data highlights circular RNAs (circRNAs) as a novel, non-invasive blood biomarker platform for the early detection of Alzheimer's Disease (AD). The research demonstrates that circRNAs ...
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, ...
Financing accelerates clinical validation and commercial readiness, as circular RNAs emerge as a new category of brain-derived blood biomarkers with best-in-class performance SAN DIEGO, Dec. 1, 2025 ...
Company taps John R. Quain, Norbert Gleicher, MD, Carol Hanna, Ph.D, Jon Hennebold, Ph.D, and Stephen Turner, Ph.D to its world-class team to advance responsible genomic medicine. NEW YORK, October 30 ...
Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Since the beginning of the semester, students in Biology 144 have been creating documentary ...
10x Genomics Inc - Class A (TXG) shares closed today at 0.1% above its 52 week low of $104.69, giving the company a market cap of $9B. The stock is currently down 29.6% year-to-date, down 40.3% over ...
Deep Genomics, the AI driven genetic medicine company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied by early stage ...
City College student Thomas Hurt pointed at a computer screen showing a breakdown of his own DNA and said, “That right here, this is me.” Hurt, 26, and dozens of other City College undergraduate ...
10x Genomics Inc - Class A (TXG) shares closed today at 1.5% above its 52 week low of $117.01, giving the company a market cap of $11B. The stock is currently down 18.1% year-to-date, down 27.2% over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback